Christine Hunt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5685906/publications.pdf

Version: 2024-02-01

35 papers	2,497 citations	361388 20 h-index	377849 34 g-index
37 all docs	37 docs citations	37 times ranked	2716 citing authors

#	Article	IF	Citations
1	Case Definition and Phenotype Standardization in Drug-Induced Liver Injury. Clinical Pharmacology and Therapeutics, 2011, 89, 806-815.	4.7	773
2	Effect of age and gender on the activity of human hepatic CYP3A. Biochemical Pharmacology, 1992, 44, 275-283.	4.4	393
3	Clinical relevance of hepatitis B viral mutations. Hepatology, 2000, 31, 1037-1044.	7.3	324
4	Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial. Hepatology, 2000, 32, 135-138.	7.3	162
5	Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in VigiBaseâ„¢. Drug Safety, 2010, 33, 503-522.	3.2	142
6	Effect of orthotopic liver transplantation on employment and health status. Liver Transplantation, 1996, 2, 148-153.	1.8	63
7	Drug-induced liver injury following positive drug rechallenge. Regulatory Toxicology and Pharmacology, 2009, 54, 84-90.	2.7	54
8	Drug rechallenge following drugâ€induced liver injury. Hepatology, 2017, 66, 646-654.	7.3	50
9	Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBaseâ„¢. Regulatory Toxicology and Pharmacology, 2015, 72, 481-490.	2.7	46
10	Age-related differences in reporting of drug-associated liver injury: Data-mining of WHO Safety Report Database. Regulatory Toxicology and Pharmacology, 2014, 70, 519-526.	2.7	45
11	Co-medications That Modulate Liver Injury and Repair Influence Clinical Outcome of Acetaminophen-Associated Liver Injury. Clinical Gastroenterology and Hepatology, 2009, 7, 882-888.	4.4	38
12	Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. Pharmacogenomics, 2013, 14, 541-554.	1.3	37
13	Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: A systematic review. Hepatology, 2010, 52, 2216-2222.	7.3	33
14	Risk factors for biopsyâ€proven advanced nonâ€alcoholic fatty liver disease in the Veterans Health Administration. Alimentary Pharmacology and Therapeutics, 2018, 47, 268-278.	3.7	33
15	Characterizing phenotypes and outcomes of drugâ€associated liver injury using electronic medical record data. Pharmacoepidemiology and Drug Safety, 2013, 22, 190-198.	1.9	32
16	APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program. JAMA Internal Medicine, 2022, 182, 386.	5.1	31
17	Interplay of gender, age and drug properties on reporting frequency of drug-induced liver injury. Regulatory Toxicology and Pharmacology, 2018, 94, 101-107.	2.7	29
18	Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration. Digestive Diseases and Sciences, 2018, 63, 2259-2266.	2.3	26

#	Article	IF	Citations
19	Children's liver chemistries vary with age and gender and require customized pediatric reference ranges. Regulatory Toxicology and Pharmacology, 2015, 73, 349-355.	2.7	23
20	Effect of postoperative complications on health and employment following liver transplantation. Clinical Transplantation, 1998, 12, 99-103.	1.6	23
21	Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease. Regulatory Toxicology and Pharmacology, 2008, 52, 85-88.	2.7	21
22	Regulation of rat hepatic cytochrome P450IIE1 in primary monolayer hepatocyte culture. Xenobiotica, 1991, 21, 1621-1631.	1.1	19
23	Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both?. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2019, 36, 64-71.	0.6	19
24	Liver disease in pregnancy. American Family Physician, 1999, 59, 829-36.	0.1	19
25	A pre-marketing ALT signal predicts post-marketing liver safety. Regulatory Toxicology and Pharmacology, 2012, 63, 433-439.	2.7	14
26	Validation of Multivariate Outlier Detection Analyses Used to Identify Potential Drug-Induced Liver Injury in Clinical Trial Populations. Drug Safety, 2012, 35, 865-875.	3.2	12
27	A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data. Pharmacoepidemiology and Drug Safety, 2013, 22, 571-578.	1.9	12
28	Prevalence and incidence of liver enzyme elevations in a pooled oncology clinical trial cohort. Regulatory Toxicology and Pharmacology, 2016, 77, 257-262.	2.7	9
29	Expanding our toolkit to better identify drugâ€induced liver injury in electronic medical records. Liver International, 2018, 38, 585-587.	3.9	4
30	The evaluation of drug rechallenge: The casopitant Phase III program. Regulatory Toxicology and Pharmacology, 2010, 58, 539-543.	2.7	3
31	Proton-pump inhibitor use is not associated with severe COVID-19-related outcomes: a propensity score-weighted analysis of a national veteran cohort. Gut, 2022, 71, 1447-1450.	12.1	3
32	Hepatitis B Virus-related Care Quality in Patients With Hepatitis B/Human Immunodeficiency Virus Coinfection Versus Hepatitis B Monoinfection: A National Cohort Study. Clinical Infectious Diseases, 2022, 75, 1529-1536.	5.8	3
33	Implementation of Pharmacogenetic Testing Within the Veterans Health Administration From 2011 to 2013. Military Medicine, 2016, 181, 1375-1381.	0.8	1
34	Identifying and Treating Nonalcoholic Fatty Liver Disease. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2019, 36, 20-29.	0.6	1
35	Editorial: diabetes, obesity and clinical inertiaâ€"the recipe for advanced <scp>NASH</scp>. Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 1221-1222.	3.7	0